Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) filed this Form 8-K on September 10, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market. The filing addresses a regulatory notice regarding the company's continued listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a listing deficiency notice.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq. The company's common stock closing bid price remained below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has an initial 180-day period (expiring March 10, 2025) to regain compliance. Compliance requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Delisting Risk: If compliance is not achieved within the initial period, the company may be eligible for an additional 180-day period, contingent on transferring to the Nasdaq Capital Market and meeting its listing standards. Failure to cure the deficiency could result in delisting.
- Appeal Process: If delisting is proposed, the company may appeal to a Hearings Panel. The stock would likely remain listed pending the decision, though success is not guaranteed.
- Management Action: Management intends to actively monitor the stock price and evaluate options to regain compliance but provided no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of XLO stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of compliance before the March 10, 2025 deadline.
- Review future filings for any announcements regarding a potential transfer to the Nasdaq Capital Market.
- Check for any subsequent communications from Nasdaq regarding extensions or delisting determinations.